ACA
MGRX icon

Ackerman Capital Advisors’s Mangoceuticals MGRX Stock Holding History

Ackerman Capital Advisors’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4K Hold
34,500
– – ﹤0.01% 115
2025
Q4 		$25.5K Hold
34,500
– – 0.01% 121
2025
Q3 		$75.6K Hold
34,500
– – 0.02% 116
2025
Q2 		$52.4K Hold
34,500
– – 0.01% 112
2025
Q1 		$67.3K Hold
34,500
– – 0.02% 108
2024
Q4 		$83.5K Sell
34,500
-23,724
-41% -$62.2K 0.02% 99
2024
Q3 		$206K Buy
+58,224
New +$275K 0.05% 92

Other funds holding MGRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Ackerman Capital Advisors's MGRX Position: Q1 2026 in Review

Ackerman Capital Advisors held its Mangoceuticals (MGRX) position steady in Q1 2026 at 34,500 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #115.

Ackerman Capital Advisors first reported a position in MGRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $206K in Q3 2024. 18 funds tracked by Wall St. Rank hold MGRX as of Q1 2026.

  • Ackerman Capital Advisors held 34,500 shares of Mangoceuticals worth $12.4K as of Q1 2026.
  • Ackerman Capital Advisors left its Mangoceuticals share count unchanged in Q1 2026.
  • Mangoceuticals made up ﹤0.01% of Ackerman Capital Advisors's portfolio in Q1 2026, its #115 holding.
  • Ackerman Capital Advisors first reported a position in Mangoceuticals in Q3 2024 and has held it in 7 quarters since.
  • Ackerman Capital Advisors's Mangoceuticals position peaked at $206K in Q3 2024.
  • 18 funds tracked by Wall St. Rank held Mangoceuticals as of Q1 2026.

Based on Ackerman Capital Advisors's 13F filing for Q1 2026, filed 5 May 2026.